Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Child's Nervous System
Published in: Child's Nervous System 7/2020

Open Access 01-07-2020 | Craniopharyngioma | Original Article

Ki67 as a prognostic factor of craniopharyngioma’s recurrence in paediatric population

Authors: Elżbieta Moszczyńska, Monika Prokop-Piotrkowska, Agnieszka Bogusz-Wójcik, Wiesława Grajkowska, Sylwia Szymańska, Mieczysław Szalecki

Published in: Child's Nervous System | Issue 7/2020

Login to get access

Abstract

Purpose

Craniopharyngioma is one of the most frequent benign tumours of the central nervous system in the paediatric population. Although it is a benign tumour according to the WHO classification, it significantly deteriorates the patient’s quality of life. The aim of this study is to assess if proliferation index Ki67 can be a useful marker of the risk of craniopharyngioma’s recurrence.

Methods

Expression of Ki67 was examined in 85 specimens of primary craniopharyngioma and in 11 specimens of the recurring tumour. In all the cases, adamantinomatous type of craniopharyngioma was diagnosed. Values of Ki67 expression were compared between patients with and without recurrence, between patients with progression and relapse and between primary and recurrent tumours.

Results

No statistically significant differences were found between proliferation index Ki67 values in tumours with recurrence and without (median values 2.5% and 3%, respectively, p = 0.69). The median value of proliferation index Ki67 in progression group was 1% and in the relapse group 4%; no statistical significance between those groups was found (p = 0.067). The median value of proliferation index Ki67 in primary tumours was 3% (0–20%) and in recurrent tumours it was 5% (0–14%). Despite the lack of statistical significance (p = 0.61), a tendency towards higher values of Ki67 in recurring tumours in comparison with primary tumours was shown.

Conclusions

Proliferation index Ki67 is not a reliable prognostic factor of craniopharyngioma’s recurrence.
Literature
1.
Lopes MBS (2017) The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 134(4):521–535CrossRef
2.
Nelson J.S., Parisi J. E., Schochet S.S. Jr, Mena H. (1993) Nonglial tumours. Principles and practice of neuropathology. 203–266 pp.
3.
4.
Schoenberg BC, Schoenberg DG, Christine BW (1976) The epidemiology of primary intracranial neoplasm of childhood. A population study. Mayo Clin Proc 51:51–56PubMed
5.
De Vile CJ, Grant DB, Hayward RD, Kendall BE, Neville BGR, Stanhope R (1996) Obesity in childhood craniopharyngioma: relation to post-operative hypothalamic damage shown by magnetic resonance imaging. J Clin Endocrinol Metab 81(7):2734–2737PubMed
6.
Moszczyńska E, Szalecki M, Pasternak-Pietrzak K, Jurkiewicz E, Szymańska S (2017) Craniopharyngioma – epidemiology, pathogenesis, imaging, clinical symptoms. Endokrynol Ped 16:205–220
7.
Nielsen EH, Feldt-Rasmussen U, Poulsgaard L, Kristensen L, Astrup J, Jørgensen JO, Bjerre P, Andersen M, Andersen C, Jørgensen J, Lindholm J, Laurberg P (2011) Incidence of craniopharyngioma in Denmark (n = 189) and estimated world incidence of craniopharyngioma in children and adults. J Neuro-Oncol 104(3):755–763CrossRef
8.
9.
Gucev ZS, Danilovski D, Tasic V, Ugrinovski J, Nastova V, Jancevska A, Krstevska-Konstantinova M, Pop-Jordanova N, Kirovski I (2011) Childhood craniopharyngioma in Macedonia: incidence and outcome after subtotal resection and cranial irradiation. World J Pediatr 7(1):74–78CrossRef
10.
Zacharia BE, Bruce SS, Goldstein H, Malone HR, Neugut AI, Bruce JN. (2012) Epidemiology and end results program 14(8):1070–8
11.
Kim SK, Wang KC, Shin SH, Choe G, Chi JG, Cho BK et al (2001) Radical excision of pediatric craniopharyngioma: recurrence pattern and prognostic factors. Childs Nerv Syst 17(9):531–536CrossRef
12.
Van Effenterre R, Boch A-L (2002) Craniopharyngioma in adults and children: a study of 122 surgical cases. J Neurosurg 97:3–11CrossRef
13.
14.
Izumoto S, Suzuki T, Kinoshita M, Hashiba T, Kagawa N, Wada K, Fujimoto Y, Hashimoto N, Saitoh Y, Maruno M, Yoshimine T (2005) Immunohistochemical detection of female sex hormone receptors in craniopharyngiomas: correlation with clinical and histologic features. Surg Neurol 63(6):520–525CrossRef
15.
Losa M, Vimercati A, Acerno S, Barzaghi RL, Mortini P, Mangili F et al (2004) Correlation between clinical characteristics and proliferative activity in patients with craniopharyngioma. J Neurol Neurosurg Psychiatry 75(6):889–892CrossRef
16.
Agozzino L, Ferraraccio F, Accardo M, Esposito S, Agozzino M, Cuccurullo L (2006) Morphological and ultrastructural findings of prognostic impact in craniopharyngiomas. Ultrastruct Pathol 30(3):143–150CrossRef
17.
Dickey T, Raghaven R (1999) RE. MIB-1, Ki67, immunoreactivity as predictor of the risk of recurrence of craniopharyngioma. J Neuropathol Exp Neurol 58:567–576CrossRef
18.
Yalcin N, Akbulut M, Çagli S et al (2009) Prognostic significance of the Ki–67 labeling index and P53 protein expression for patient with craniopharyngioma. J Neurol Sci Turk 26(3):286–291
19.
Raghavan R, Dickey WT, Margraf LR, White CL, Coimbra C, Hynan LS et al (2000) Proliferative activity in clinicopathological correlations in adults and children. Surg Neurol 54(00):241–248CrossRef
20.
Torunishi, Kuratsu JI, Takeshima H, Saito Y, Kochi M, Ushio Y (1999) Prognostic significance of the MIB-1 labeling index for patient with craniopharyngioma. Int J Mol Med 3(2):157–161
21.
Duò D, Gasverde S, Benech F (2003) MIB-1 immunoreactivity in craniopharyngiomas: a clinico-pathological analysis. Clin Neuropathol 22(5):229–234PubMed
22.
Momota H, Ichimiya S, Ikeda T, Yamaki T, Kikuchi T, Houkin K, Sato N (2003) Immunohistochemical analysis of the p53 family members in human craniopharyngiomas. Brain Tumor Pathol 20(2):73–77CrossRef
23.
Cao J, Lin JP, Yang LX (2010) Expression of aberrant β-catenin p-63 in craniopharyngioma. Br J Neurosurg 24(3):249–256CrossRef
24.
25.
Tena-Suck ML, Salinas-Lara C, Arce-Arellano RI, Rembao-Bojórquez D, Morales-Espinosa D, Sotelo J, Arrieta O (2006) Clinico-pathological and immunohistochemical characteristics associated to recurrence/regrowth of craniopharyngiomas. Clin Neurol Neurosurg 108(7):661–669CrossRef
26.
Hofmann BM, Hoelsken A, Fahlbusch R, Blümcke I, Buslei R (2010) Hormone receptor expression in craniopharyngiomas: a clinicopathological correlation. Neurosurgery. 67(3):617–625CrossRef
27.
28.
29.
Honegger J, Buchfelder M, Fahlbusch R (1999) Surgical treatment of craniopharyngiomas: endocrinological results. J Neurosurg 90(2):251–257CrossRef
30.
Tena-Suck ML, Hernandez-Campos E, Citlaltepetl Salinas L (2014) Rosenthal fibers in craniopharyngioma: a clinicopathologic and immunohistochemical approach. Neurosurg. 24(2):146–154CrossRef
31.
Vidal S, Kovacs K, Lloyd RV, Meyer FB, Scheithauer BW (2002) Angiogenesis in patients with craniopharyngiomas: correlation with treatment and outcome. Cancer. 94(3):738–745CrossRef
32.
33.
Xia Z, Liu W, Li S (2011) Expression of matrix metalloproteinase-9, type IV collagen and vascular endothelial growth factor in adamantinous craniopharyngioma. Neurochem Res 36:2346–2351CrossRef
34.
Lubansu A, Ruchoux M, Brotchi J, Salmon I, Kiss R, Lefranc F (2003) Cathepsin B , D and K expression in adamantinomatous craniopharyngiomas relates to their levels of differentiation as determined by the patterns of retinoic acid receptor expression. Histopathology 43:563–572CrossRef
35.
Gong J, Zhang H, Xing S, Li C, Ma Z, Jia G, Hu W (2014) High expression levels of CXCL12 and CXCR4 predict recurrence of adamantinomatous craniopharyngiomas in children. Cancer Biomark 14(4):241–251CrossRef
36.
Gomes DC, Jamra SA, Leal LF, Colli LM, Campanini ML, Oliveira RS (2015) Sonic Hedgehog pathway is upregulated in adamantinomatous craniopharyngiomas. Eur J Endocrinol 172(5):603–608CrossRef
37.
Veiga C, Vieira R, Cirqueira S, Delano M, Claudia M, Zerbini N et al (2017) Differential expression of stem cell markers in human adamantinomatous craniopharyngioma and pituitary adenoma. Neuroendocrinology 900:183–193
38.
Guadagno E, De Divitiis O, Solari D, Borrelli G, Bracale UM, Di Somma A et al (2017) Can recurrences be predicted in craniopharyngiomas ? β -catenin coexisting with stem cells markers and p-ATM in a clinicopathologic study of 45cases. J Exp Clin Cancer Res:1–11
39.
Omay SB, Chen Y, Almeida JP, Ruiz-treviño AS, Boockvar JA, Stieg PE et al (2018) Do craniopharyngioma molecular signatures correlate with clinical characteristics? J Neurosurg 128(May):1473–1478CrossRef
40.
41.
Ogawa Y, Watanabe M, Tominaga T (2013) Rathke’s cleft cysts with significant squamous metaplasia — high risk of postoperative deterioration and close origins to craniopharyngioma. Acta Neurochir 155(6):1069–1075CrossRef
42.
Hall PA, Woods AL (1990) Immunohistochemical markers of cellular proliferation: achievements, problems and prospects. Cell Prolif 23(6):505–522CrossRef
43.
Synchronization C, Harper JV (1993) Synchronization of cell populations in G1/S and G2/M phases of the cell cycle. Cell Cycle Control 296(1):157–166
44.
Sofela AA, Hettige S, Curran O, Bassi S (2014) Malignant transformation in craniopharyngiomas. Neurosurgery. 75(3):306–314CrossRef
45.
Chargari C, Bauduceau O, Bauduceau B et al (2007) Craniopharyngiomas: role of radiotherapy. Bull Cancer 94(11):987–994PubMed
46.
Ohashi R (2018) Prognostic utility of atypical mitoses in patients with breast cancer : a comparative study with Ki67 and phosphohistone H3. J Surg Oncol 118(3):557–567PubMed
47.
Lin S, Wang M (2018) Pooling analysis on prognostic value of PHH3 expression in cancer patients. Cancer Manag Res 10:2279–2288CrossRef
Metadata
Title
Ki67 as a prognostic factor of craniopharyngioma’s recurrence in paediatric population
Authors
Elżbieta Moszczyńska
Monika Prokop-Piotrkowska
Agnieszka Bogusz-Wójcik
Wiesława Grajkowska
Sylwia Szymańska
Mieczysław Szalecki
Publication date
01-07-2020
Publisher
Springer Berlin Heidelberg
Published in
Child's Nervous System / Issue 7/2020
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI
https://doi.org/10.1007/s00381-020-04519-4

Other articles of this Issue 7/2020

Child's Nervous System 7/2020 Go to the issue

Original Article

Postoperative patency assessment of Cystocisternostomy and Cystoventriculostomy stomas in cases with Arachnoidal cyst

Book Review

H. Lanfermann, P. Raab, H-J Kretschmann, and W. Weinrich (Editors): Cranial neuroimaging and clinical neuroanatomy (fourth edition)

Letter to the Editor

Suboccipital decompressive craniectomy in a case of complex Chiari malformation complicated with influenza A (H1N1) necrotizing encephalopathy

Letter to the Editor

An intermediate form of dysraphism: the MyeLDM

Original Article

Visualization of skull remodeling and re-ossification after reconstructive surgery and mosaic-like cranioplasty in sagittal synostosis and deformational brachycephaly1

Cover Editorial

Sir Richard Owen (1804–1892) and his work on the developing skull